Immunotherapy in Non-small Cell Lung Cancers

Dear Colleagues,

Within the last few years, immune checkpoint inhibitors (ICIs) have rapidly become the standard of care for advanced non-small cell lung cancer (NSCLC) without oncogenic drivers. Recent evidence has led to their use even at the early stages as adjuvant and/or neoadjuvant treatment.

Certainly, immunotherapy has been shown to significantly improve patient survival compared with chemotherapy alone. However, there are still areas of unmet needs. Most patients develop resistance to treatment during the course of the disease, and only a minority of them have long-term benefits. PD-L1 expression is the only biomarker validated in clinical practice, but some limitations reduce its reliability, including mainly spatial and temporal heterogeneity. Several other biomarkers are under investigation, both tissue- and blood-derived, but need validation. Combination strategies (ICIs plus platinum-based chemotherapy) have emerged to increase response rates and survival, but not all patients respond or are eligible for chemotherapy.

This Special Issue aims to provide an overview of the current role of immunotherapy in NSCLC, but also gather new findings for future perspectives.

Dr. Marco Russano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• non-small cell lung cancer
• immune checkpoint inhibitors
• PD-1/PD-L1 blockade
• immunotherapy
• biomarkers